A Case of Systemic Severe Bullous Pemphigoid Caused by Long-Term Sintilimab Treatment for Renal Cell Carcinoma

被引：3

作者：

He, Jia ^{[1
]}

Duan, Xi ^{[1
]}

Liu, Ting ^{[1
]}

Yang, Hao ^{[1
]}

Jiang, Jingjing ^{[1
]}

Mu, Yunzhu ^{[1
,2
]}

机构：

[1] North Sichuan Med Coll, Dept Dermatol, Affiliated Hosp, Nanchong, Peoples R China

[2] North Sichuan Med Coll, Dept Dermatol, Affiliated Hosp, 1 Maoyuan South Rd, Nanchong 637000, Sichuan, Peoples R China

来源：

CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY | 2022年 / 15卷

关键词：

bullous pemphigoid; PD; -1; -L1; sintilimab;

D O I：

10.2147/CCID.S374449

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Immune-related adverse events have been reported in relation to programmed cell death protein-1 (PD-1). However, there are few reports on PD-1 inhibitor-induced bullous pemphigoid. We report the case of a patient who developed bullous pemphigoid following long-term administration of sintilimab for renal cell carcinoma. He developed scattered erythema, blisters, and generalized pruritus for 1 week before admission. Histopathology showed subepidermal blisters and direct immunofluorescence showed linear deposition of immunoglobulin G and complement 3 on the basement membrane; the level of BP180 was 146.93U/mL. A regimen containing methylprednisolone, minocycline, and niacinamide was administered and the patient was discharged following resolution of symptoms.

引用

页码：1611 / 1614

页数：4